NanoViricides reports NV-CoV-2-R shows nearly 2x intact remdesivir in plasma vs standard in rat study

NANOVIRICIDES, INC.

Almost double intact remdesivir in plasma on day 1 of dosing with NV-CoV-2-R vs standard remdesivir.
After fifth dose (day 7), circulating remdesivir 75% greater in NV-CoV-2-R group.
NV-CoV-2-R combines nanoviricides platform attack on virus outside cells with remdesivir inside cells.
Company expects improved pan-coronavirus activity retaining effectiveness against emerging variants.
Draft data inadvertently published; final press release expected by September 28, 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.